Genetics of coronary heart disease: current knowledge and research principles.

[1]  N. Holtzman,et al.  Will genetics revolutionize medicine? , 2000, The New England journal of medicine.

[2]  X. Jeunemaître,et al.  The future of genetic association studies in hypertension: improving the signal‐to‐noise ratio , 2000, Journal of hypertension.

[3]  L. Cardon,et al.  Waiting for the working draft from the human genome project , 2000, BMJ : British Medical Journal.

[4]  Sui Huang,et al.  The practical problems of post-genomic biology , 2000, Nature Biotechnology.

[5]  G. Jensen,et al.  Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. , 2000, Circulation.

[6]  C. Kumana,et al.  Association studies of genetic polymorphisms and complex disease , 2000, The Lancet.

[7]  R. Frikke-Schmidt,et al.  Apolipoprotein E genotype: epsilon32 women are protected while epsilon43 and epsilon44 men are susceptible to ischemic heart disease: the Copenhagen City Heart Study. , 2000, Journal of the American College of Cardiology.

[8]  P. Grant,et al.  Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. , 2000, Blood.

[9]  B. Winkelmann,et al.  Genetic variation in coronary heart disease and myocardial infarction: methodological overview and clinical evidence. , 2000, Pharmacogenomics.

[10]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[11]  Sarah Parish,et al.  Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls , 1999, The Lancet.

[12]  C. Hengstenberg,et al.  No association of the I/D polymorphism of the angiotensin-converting enzyme with myocardial infarction in 4941 probands , 1999 .

[13]  John A Todd,et al.  Interpretation of results from genetic studies of multifactorial diseases , 1999, The Lancet.

[14]  M. Margaglione,et al.  Prothrombotic genetic risk factors in young survivors of myocardial infarction. , 1999, Blood.

[15]  L Tiret,et al.  Sequence diversity in 36 candidate genes for cardiovascular disorders. , 1999, American journal of human genetics.

[16]  B. Nordestgaard,et al.  Lipoprotein Lipase Mutations, Plasma Lipids and Lipoproteins, and Risk of Ischemic Heart Disease A Meta-Analysis , 1999 .

[17]  G. Assmann,et al.  Strategies for the assessment of genetic coronary artery disease risk. , 1999, Current opinion in lipidology.

[18]  W. Ouwehand,et al.  Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, PlA2, Zwb) positive platelets in patients with cardiovascular disease. , 1999, European heart journal.

[19]  A. Gardemann,et al.  Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. , 1999, Blood.

[20]  D. Levy,et al.  Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[21]  M. Laule,et al.  A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study , 1999, The Lancet.

[22]  Jimmy D Bell,et al.  Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training , 1999, The Lancet.

[23]  D. Wilcken,et al.  Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. , 1998, Circulation.

[24]  P. Board,et al.  The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. , 1998, Blood.

[25]  E. Boerwinkle,et al.  Haplotype structure and population genetic inferences from nucleotide-sequence variation in human lipoprotein lipase. , 1998, American journal of human genetics.

[26]  P. Reitsma,et al.  A Genetic Propensity to High Factor VII Is not Associated with the Risk of Myocardial Infarction in Men , 1998, Thrombosis and Haemostasis.

[27]  E. Trabetti,et al.  Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. , 1998, Blood.

[28]  C. Nusbaum,et al.  Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. , 1998, Science.

[29]  A. Hofman,et al.  Elevated plasma fibrinogen: cause or consequence of cardiovascular disease? , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[30]  W. März,et al.  Polymorphism of Platelet Membrane Glycoprotein IIIa: Human Platelet Antigen 1b (HPA-1b/PlA2) Is an Inherited Risk Factor for Premature Myocardial Infarction in Coronary Artery Disease , 1998, Thrombosis and Haemostasis.

[31]  J W Jukema,et al.  The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. , 1998, The New England journal of medicine.

[32]  P. de Knijff,et al.  Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. , 1998, The New England journal of medicine.

[33]  K P Fung,et al.  A genome-based resource for molecular cardiovascular medicine: toward a compendium of cardiovascular genes. , 1997, Circulation.

[34]  S. Humphries,et al.  Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. , 1997, Atherosclerosis.

[35]  R. Kunz,et al.  Association between the angiotensinogen 235T-variant and essential hypertension in whites: a systematic review and methodological appraisal. , 1997, Hypertension.

[36]  H. Prydz,et al.  Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[37]  P Corvol,et al.  Molecular genetics of human hypertension: role of angiotensinogen. , 1997, Endocrine reviews.

[38]  N. Schork,et al.  Genetics of complex disease: approaches, problems, and solutions. , 1997, American journal of respiratory and critical care medicine.

[39]  J. Boer,et al.  Lipoprotein lipase variants D9N and N291S are associated with increased plasma triglyceride and lower high-density lipoprotein cholesterol concentrations: studies in the fasting and postprandial states: the European Atherosclerosis Research Studies. , 1997, Circulation.

[40]  S. Humphries,et al.  Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. , 1997, Circulation.

[41]  G. Schellenberg,et al.  Evidence that the apolipoprotein E-genotype effects on lipid levels can change with age in males: a longitudinal analysis. , 1997, American journal of human genetics.

[42]  A. Gardemann,et al.  Positive Association of the β Fibrinogen H1/H2 Gene Variation to Basal Fibrinogen Levels and to the Increase in Fibrinogen Concentration during Acute Phase Reaction but not to Coronary Artery Disease and Myocardial Infarction , 1997, Thrombosis and Haemostasis.

[43]  D. Arveiler,et al.  The Leu33/Pro Polymorphism (PIA1/PIA2 ) of the Glycoprotein IIIa (GPIIIa) Receptor Is Not Related to Myocardial Infarction in the ECTIM Study , 1997, Thrombosis and Haemostasis.

[44]  L. Tiret,et al.  Coronary heart disease and genetics in epidemiologist's view. , 1997, Molecular medicine today.

[45]  D. Mari,et al.  Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins. A study in centenarians. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[46]  P. Schnohr,et al.  A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. , 1997, The Journal of clinical investigation.

[47]  M. Kritzik,et al.  Hereditary variation in platelet integrin α2β1 density is associated with two silent polymorphisms in the α2 gene coding sequence , 1997 .

[48]  J. Boer,et al.  Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[49]  P. Ridker,et al.  PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis , 1997, The Lancet.

[50]  J. Wang,et al.  Polymorphisms of factor V, factor VII, and fibrinogen genes. Relevance to severity of coronary artery disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[51]  P. Ridker,et al.  Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. , 1997, Circulation.

[52]  E. Barrett-Connor.  Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. , 1997, Circulation.

[53]  N Risch,et al.  The Future of Genetic Studies of Complex Human Diseases , 1996, Science.

[54]  B. Winkelmann,et al.  Deletion Polymorphism of the Angiotensin I-Converting Enzyme Gene Is Associated with Increased Plasma Angiotensin-Converting Enzyme Activity but Not with Increased Risk for Myocardial Infarction and Coronary Artery Disease , 1996, Annals of Internal Medicine.

[55]  D. Wilcken,et al.  Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[56]  D. Galton,et al.  Identification of putative beneficial mutations for lipid transport. , 1996, Zeitschrift fur Gastroenterologie.

[57]  J. Weiss,et al.  A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. , 1996, The New England journal of medicine.

[58]  D. Arveiler,et al.  Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du Myocarde. , 1996, Circulation.

[59]  D. Arveiler,et al.  Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. , 1996, Atherosclerosis.

[60]  S. Humphries,et al.  The 4G/5G Genetic Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Is Associated with Differences in Plasma PAI-1 Activity but not with Risk of Myocardial Infarction in the ECTIM Study , 1995, Thrombosis and Haemostasis.

[61]  P. Talmud,et al.  DNA polymorphisms of the apoprotein B gene are associated with altered plasma lipoprotein concentrations but not with perceived risk of cardiovascular disease: European Atherosclerosis Research Study. , 1995, Atherosclerosis.

[62]  T. Yee,et al.  Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease , 1995, The Lancet.

[63]  A. Hamsten,et al.  Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[64]  A. Evans,et al.  Genetic variation at the angiotensinogen locus in relation to high blood pressure and myocardial infarction , 1995, Journal of Hypertension.

[65]  P A Wolf,et al.  Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. , 1994, JAMA.

[66]  G. Mcclearn,et al.  Genetic and environmental correlations among serum lipids and apolipoproteins in elderly twins reared together and apart. , 1994, American journal of human genetics.

[67]  L. Berkman,et al.  Genetic susceptibility to death from coronary heart disease in a study of twins. , 1994, The New England journal of medicine.

[68]  R. Ward,et al.  Apolipoprotein Polymorphisms Fail to Define Risk of Coronary Artery Disease: Results of a Prospective, Angiographically Controlled Study , 1994, Circulation.

[69]  J. Ott,et al.  Molecular and statistical approaches to the detection and correction of errors in genotype databases. , 1993, American journal of human genetics.

[70]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[71]  L. Kuller,et al.  Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. , 1993, The American journal of cardiology.

[72]  Philippe Amouyel,et al.  Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction , 1992, Nature.

[73]  S. Humphries,et al.  Variation in the Promoter Region of the β Fibrinogen Gene Is Associated with Plasma Fibrinogen Levels in Smokers and Non-Smokers , 1991, Thrombosis and Haemostasis.

[74]  P Corvol,et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.

[75]  J. Buring,et al.  Apolipoprotein B-gene DNA polymorphisms associated with myocardial infarction. , 1986, The New England journal of medicine.

[76]  G. Assmann,et al.  Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. , 1986, Clinical chemistry.

[77]  R. Ross.  The pathogenesis of atherosclerosis--an update. , 1986, The New England journal of medicine.

[78]  M. Blombäck,et al.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.

[79]  J. Fleiss,et al.  A simple approximation for calculating sample sizes for comparing independent proportions. , 1980, Biometrics.

[80]  J. Tukey.  Some thoughts on clinical trials, especially problems of multiplicity. , 1977, Science.

[81]  A. Beaudet.  Making Genomic Medicine a Reality , 1999 .

[82]  A. Carter,et al.  Association of a Common Polymorphism in the Factor XIII Gene with Myocardial Infarction , 1998, Thrombosis and Haemostasis.

[83]  I. Borecki,et al.  Associations between candidate loci angiotensin-converting enzyme and angiotensinogen with coronary heart disease and myocardial infarction: the NHLBI Family Heart Study. , 1997, Annals of epidemiology.

[84]  S. Mann,et al.  Ciba Foundation Symposium , 1997 .

[85]  N. Ossei-Gerning,et al.  Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[86]  J. Kastelein,et al.  Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. , 1997, Circulation.

[87]  C. Sing,et al.  Genetic architecture of common multifactorial diseases. , 1996, Ciba Foundation symposium.

[88]  P. Talmud,et al.  European Atherosclerosis Research Study: genotype at the fibrinogen locus (G-455-A beta-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Evidence for gender-genotype-environment interaction. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[89]  C. Sing,et al.  Biological complexity and strategies for finding DNA variations responsible for inter-individual variation in risk of a common chronic disease, coronary artery disease. , 1992, Annals of medicine.

[90]  C. Sing,et al.  Apolipoprotein E polymorphism and atherosclerosis. , 1988, Arteriosclerosis.